NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for

JEPI's monthly payouts have quietly shrunk all year while the broader market surged past it, and the

Retirees rarely want excitement from an income holding. They want a check that arrives, gets bigger,

J&J's portfolio primarily includes small biotech and medtech companies. Its largest investment is in

Converting a nest egg into a reliable monthly paycheck sounds straightforward until you realize the

Deutsche Bank AG raised its position in shares of Johnson and Johnson (NYSE: JNJ) by 8.5% during the

Commerzbank Aktiengesellschaft FI boosted its position in shares of Johnson and Johnson (NYSE: JNJ)

AbbVie continues to expand its portfolio in high-growth areas like immunology and neuroscience. John

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

Johnson and Johnson and Merck are healthcare giants with dependable returns that weather economic do

A $610,000 pension lump sum sounds like freedom, but the monthly check comes with a guarantee that a

A seven-figure portfolio looks like security until federal taxes, Medicare surcharges, Social Securi

Bitcoin exposure has powered early gains in the Porter & Company Porter Portfolio Index ETF (PCPP).

Chasing a 7% blended yield across a $1.75 million portfolio sounds straightforward until you realize

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing

China's ​drug regulator has approved Johnson & Johnson's oral ‌pill for psoriasis, the company said

Imaavy can be used to treat patients aged 12 and older with warm autoimmune hemolytic anemia (wAIHA)

In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $270.27, denoting a -1.05

Attractive dividend stocks tend to have robust businesses and track records of consistent payout inc

A nest egg of $840,000 sits right at the crossroads where dividends and annuities each look surprisi

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five

Retiring at 65 on dividends sounds straightforward until you realize the number you need today at 55

August is winding down, and income-focused investors have a narrow window to line up ex-dividend dat

The yield you chase to replace a six-figure income determines not just how much capital you need, bu

JNJ's Imaavy wins FDA approval for wAIHA, becoming the first treatment specifically indicated for th

Johnson and Johnson (JNJ), the pharmaceutical and medical-technology powerhouse, held roughly flat a

At $270.24, Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a hold.

On CNBC's Squawk on the Street Monday morning, Jim Cramer said the tape has soured on the trade that

Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm auto

The yield you chase determines whether you need $1 million or $3.4 million, and the one that feels s

Bank of Montreal (TSX:BMO) beat analyst estimates in the third quarter, driven by stronger-than-expe

11:00am: Consumer confidence falls US consumer confidence and new home sales both came in below expe

With the 10-Year Treasury yielding 4.74% as of August 21, 2026, the bar for owning dividend equities

Dick's Sporting Goods (NYSE:DKS) shares plunged more than 27% on Tuesday after the retailer's second

Caitong International Asset Management Co. Ltd bought a new stake in Johnson and Johnson (NYSE: JNJ)

Founders Financial Alliance LLC lessened its position in Johnson and Johnson (NYSE: JNJ) by 10.5% in

GraniteShares Advisors LLC acquired a new stake in shares of Johnson and Johnson (NYSE: JNJ) during

Golden Reserve Retirement LLC increased its position in shares of Johnson and Johnson (NYSE: JNJ) by

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G

Chasing a fatter dividend yield can quietly destroy the very income stream you built it to replace.

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G

The U.S. ​Food and ‌Drug Administration ​has ​approved the expanded ⁠use ​of ​Johnson & Johnson's dr

The 2026 Q2 earnings cycle continues to wind down, with the reporting docket starting to get quiet.

Building $37,200 a year in dividend income is a math problem first, and the yield tier you choose ch

Johnson and Johnson (JNJ), the pharmaceutical and medical-technology powerhouse, gained approximatel

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

DALLAS--(BUSINESS WIRE)--Texas trial law firm Dean Omar Branham Shirley, LLP (DOBS) has secured a $1

JNJ's pipeline remains a key growth driver, with new launches, late-stage data and approvals support